115 results match your criteria: "The Heart and Vascular Center[Affiliation]"
Rationale and Design of the Personalized Therapy Study: Evaluating Real-World Performance of Two Automated Defibrillation Therapy Algorithms.
J Card Fail
December 2024
The Heart and Vascular Center at The Christ Hospital, Cincinnati, OH, USA. Electronic address:
Background: Barriers to maximizing patient benefit with implantable defibrillation devices include limited ability to tailor antitachycardia pacing (ATP) therapy in real-time and identify patients at risk of heart failure (HF) events early on. The Personalized Therapy study aims to evaluate the performance of two algorithms, intrinsic ATP (iATP) and TriageHF, to address these barriers in routine clinical practice.
Methods And Results: The Personalized Therapy Study was designed as a prospective, multicenter, post-market registry study expected to enroll approximately 2,200 patients meeting the following criteria: (1) implanted with a study-eligible device regardless of procedure type; (2) Medtronic CareLink® Network enrolled; (3) TriageHF enabled within CareLink and High Risk Alert notifications turned ON; and (4) iATP enabled.
Impact of cardiovascular magnetic resonance-derived right ventricular ejection fraction on adverse outcomes: A robust Bayesian model-averaged meta-analysis.
J Cardiovasc Magn Reson
December 2024
Department of Laboratory and Transfusion Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Japan.
Article Synopsis
- - This study aimed to evaluate how right ventricular ejection fraction (RVEF) relates to adverse outcomes in various cardiovascular diseases (CVD) using a Bayesian model-averaged meta-analysis approach.
- - Analysis of 108 articles with over 21,000 patients showed that while RVEF is generally associated with worse outcomes, strong evidence was mainly found for just four specific CVDs: hypertrophic cardiomyopathy, dilated cardiomyopathy, pulmonary hypertension, and aortic stenosis.
- - The study suggests that more data could improve our understanding of RVEF's impact on other types of CVD, as current evidence for those is weaker.
Redox Homeostasis and Non-Invasive Assessment of Significant Liver Fibrosis by Shear Wave Elastography.
Diagnostics (Basel)
September 2024
Department of Radiology, Semmelweis University, 1091 Budapest, Hungary.
Hepatic fibrosis with various origins can be estimated non-invasively by using certain biomarkers and imaging-based measurements. The aim of our study was to examine redox homeostasis biomarkers and liver stiffness measurements for the assessment of significant liver fibrosis in different etiologies of chronic liver diseases. A cohort study consisting of 88 chronic liver disease patients of both sexes (age 49.
View Article and Find Full Text PDFFinerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med
October 2024
From the Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) - both in the United Kingdom; National Heart Centre Singapore and Duke-National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST "Spedali Civili" Hospital, Brescia (S.N.) - all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) - all in the Netherlands; Université de Lorraine, INSERM Clinical Investigation Centre, Centre Hospitalier Universitaire, Nancy, France (F.Z.); University of Malaya, Kuala Lumpur, Malaysia (I.Z.A.); Centro de Estudios Clínicos de Querétaro, Santiago de Querétaro (M.A.A.-G.), and Hospital Cardiologico Aguascalientes, Aguascalientes (G.L.-E.) - both in Mexico; Cardiology Research Department, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia (J.J.A.); the Department of Cardiology and Angiology, Hannover Medical School, Hannover (J.B.), and Bayer, Wuppertal (P.K.) - both in Germany; Beijing Anzhen Hospital, Capital Medical University, Beijing (M.C.-S.); General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital, and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-E.C.); Emergency Institute for Cardiovascular Diseases "Prof. Dr. C.C. Iliescu," University of Medicine Carol Davila, Bucharest, Romania (O.C.); Clinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital, New Delhi, India (V.C.); the Department of Cardiology, Bellvitge University Hospital, and Bellvitge Biomedical Research Institute, Centro de Investigación Biomédica En Red Enfermedades Cardiovasculares, University of Barcelona, L'Hospitalet de Llobregat, Barcelona (J.C.-C.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens (G.F.); the Department of Internal Medicine, Hospital São Francisco Xavier, and NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal (C.F.); the Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Krakow, Poland (G.G.); the Heart Institute, Kaplan Medical Center, Rehovot, and Hebrew University, Jerusalem - both in Israel (S.G.); the Faculty of Medicine, Comenius University, Bratislava, Slovakia (E.G.); the Division of Cardiology, Severance Hospital, and Yonsei University Health System, Seoul, South Korea (S.K.); the Department of Noninvasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); St. Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City (M.N.K.); Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia (G.L.); Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Hong Kong (A.P.-W.L.); University Clinic of Lomonosov Moscow State University, Moscow (V. Mareev); Universidad Nacional de Córdoba, Córdoba, Argentina (F.A.M.); the Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V. Melenovský); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Centro Cardiovascular Colombiano, Clínica Santa María, Medellin, Colombia (C.I.S.); Cardiovascular Division, Instituto de Pesquisa Clínica de Campinas, Campinas (J.F.K.S.), and Bayer, São Paulo (F.A.) - both in Brazil; Kawaguchi Cardiovascular and Respiratory Hospital, Saitama, Japan (N.S.); the Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark (M. Schou); the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore (K.S.); Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch, New Zealand (R.T.); Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital (J.A.U.), University of Toronto (J.A.U., S.V.), and the Division of Cardiac Surgery, St. Michael's Hospital (S.V.), Toronto, and the Section of Cardiology, Max Rady College of Medicine, University of Manitoba, Winnipeg (S.Z.) - both in Canada; Heart Centre, Turku University Hospital, Turku, Finland (H.U.); the Department of Medicine, University of Minnesota, and Minneapolis VA Health Care System, Minneapolis (O.V.); the Department of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria (D.L.); National Scientific Center, Strazhesko Institute of Cardiology, National Academy of Medical Sciences, Kyiv, Ukraine (L.V.); Dokuz Eylul University Medical Faculty, Cardiology Department, Izmir, Turkey (M.B.Y.); and Bayer, Whippany, NJ (P.V.).
Article Synopsis
- Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
- In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
- Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.
N Engl J Med
November 2024
From the Department of Cardiology of German Heart Center Charité and the Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin (S.D.A., M.D., W.H.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, the Berlin Institute of Health, and DZHK Partner Site Berlin (U.L.), Deutsches Herzzentrum der Charité, the Department of Cardiology, Angiology, and Intensive Care Medicine, Campus Charité Mitte, the Center for Cardiovascular Telemedicine, and DZHK Partner Site Berlin, Charité Universitätsmedizin (F.K.), Berlin, the Departments of Cardiology and Pneumology (S.D.A., M.D., G.H., W.S.) and Medical Statistics (T.F., M.P.) and the Clinical Trial Unit (J.H.), University Medical Center Göttingen, and the Heart Center, Department of Cardiology (W.S.), Georg August University of Göttingen, DZHK Partner Site Göttingen, Göttingen, the Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz (R.S.B., M. Geyer, T.F.R.), Mainz, the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, and Cardiovascular Research Institute Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf (M. Kelm), the Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck (K.-H.K.), the West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Essen (T.R.), the Heart and Vascular Center, Bad Bevensen (U.S.), the Department of Internal Medicine I, Cardiology, University Hospital Jena, Jena (P.C.S.), the Institute for Cardiovascular Regeneration, Goethe University Frankfurt, and DZHK Partner Site Rhein-Main, Frankfurt am Main (A.Z.), the Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, and DZHK Partner Site Hamburg-Kiel-Lübeck, Hamburg (M. Karakas), the Department of Cardiology, Rostock University Medical Center, Rostock (A.Ö.), the Department of Medicine, Heart and Vascular Center, Division of Cardiology and Vascular Medicine, Johanniter Hospital Stendal, Stendal (M. Gross), the Mid-German Heart Center, Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Halle, Halle (J.T.) - all in Germany; the Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.); Baylor Scott and White Research Institute, Dallas (J.B., M.S.K.), Baylor Scott and White the Heart Hospital Plano, Plano (M.S.K.), and the Department of Medicine, Baylor College of Medicine, Temple (M.S.K.) - all in Texas; the Department of Translational Medicine, University of Ferrara, Ferrara (R.F.), the Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan (O.A.), ANMCO Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Heart Care Foundation, Florence (A.P.M.), and the Institute of Cardiology, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, and the Department of Medical and Surgical Specialties, Radiologic Sciences and Public Health, University of Brescia, Brescia (M.M., M.A.) - all in Italy; the Division of Cardiovascular Medicine, Ohio State University, Columbus (W.T.A.); the Department of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano (A.A.), and the Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich (F.R.) - both in Switzerland; the Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona (A.B.-G., E.S.-V.), and the Department of Cardiology, Hospital Universitario Ramón y Cajal, and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid (J.L.Z.) - all in Spain; the School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.G.F.C., M.C.P.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens (G.F.), and the Department of Transcatheter Heart Valves, Hygeia Hospital (K.S., M.C., P.K., K.P.), Athens, and the Department of Cardiology, St. Luke's Hospital (N.M., E.K.T.), and the European Interbalkan Medical Center (V.N., I.N., K.P.), Thessaloniki - all in Greece; the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen (F.G.); Unité Formation et Recherche Médecine, Université de Paris-Cité, site Bichat, Laboratoire de Recherche Vasculaire Translationnelle, INSERM, Groupe Hospitalier Bichat, Paris (A.V.); the Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, and the Faculty of Medicine, University of Ljubljana, Ljubljana - both in Slovenia (M.L.); the Division of Cardiology and Structural Heart Diseases (G.S., W.W.) and the Department of Cardiology, Congenital Heart Diseases, and Electrotherapy (Z.K.), Medical University of Silesia, Katowice, the Institute of Heart Diseases, Medical University and University Hospital, Wrocław (K.R., P.P.), and the Department of Interventional Cardiology, Department of Radiology and Diagnostic Imaging, John Paul II Hospital, Krakow (Ł.W.) - all in Poland; and Centro Academico de Medicina de Lisboa, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal (F.J.P.).
Article Synopsis
- The study examined the effectiveness of transcatheter mitral-valve repair in patients suffering from heart failure and functional mitral regurgitation, comparing it to standard medical therapy.
- In a trial with 505 patients, results showed that those who received the device had significantly lower rates of hospitalizations for heart failure and cardiovascular death compared to those who only received medical therapy.
- Additionally, patients in the device group experienced a greater improvement in health status, as measured by the Kansas City Cardiomyopathy Questionnaire, indicating better outcomes with the transcatheter procedure.
Artificial Intelligence-Enabled Quantitative Coronary Plaque and Hemodynamic Analysis for Predicting Acute Coronary Syndrome.
JACC Cardiovasc Imaging
September 2024
McGovern Medical School, University of Texas Health Sciences Center, Houston, Texas, USA.
Article Synopsis
- A study was conducted to improve the prediction of which coronary artery lesions could lead to acute coronary syndrome (ACS) by integrating artificial intelligence (AI) with traditional methods.
- The research focused on patients who had undergone coronary CT angiography (CTA) before experiencing an ACS event, analyzing both culprit (problematic) and nonculprit lesions.
- The new model incorporating AI features showed significantly better predictability for identifying high-risk lesions compared to standard methods, suggesting that AI can enhance cardiac risk assessment.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med
May 2024
From the Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center (C.M.G., S.K., G.C.), and the Department of Medicine, Cardiovascular Division (P.L.), and the Center for Cardiovascular Disease Prevention (P.M.R.), Brigham and Women's Hospital (F.M.S.), Harvard Medical School, and the Harvard T.H. Chan School of Public Health (F.M.S.) - all in Boston; CSL Behring, King of Prussia, PA (D.D., M.H., P.T., L.I.D., S.J.M.); INECO Neurociencias, Rosario, Argentina (M.C.B.); Duke Clinical Research Institute, Duke Health, Durham, NC (J.H.A., R.D.L., T.J.P.); the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo (J.C.N.), and the Brazilian Clinical Research Institute (R.D.L.) - both in Sao Paulo; the Heart and Vascular Center of Semmelweis University, Budapest, Hungary (B.M.); Lady Davis Carmel Medical Center, Haifa, Israel (B.S.L.); Radboud University Medical Center, Nijmegen and Noordwest Ziekenhuisgroep, Alkmaar (J.H.C.), and the University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.) - both in the Netherlands; Krakowski Szpital Specjalistyczny im. Jana Pawła II, Krakow (J.T.), and the Department of Cardiology and Structural Heart Disease, School of Medicine in Katowice, Medical University of Silesia, Katowice (M.T.) - both in Poland; the National Scientific Center, Kyiv, Ukraine (A.P.); the University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (M.B.); the Canadian VIGOUR Centre, University of Alberta, Edmonton, and St. Michael's Hospital, Unity Health Toronto, and Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto - all in Canada (S.G.G.); Mount Sinai Fuster Heart Hospital (D.L.B.) and Zena and Michael A. Wiener Cardiovascular Institute (R.M.), Icahn School of Medicine at Mount Sinai, and Weill Cornell Medicine (R.A.H.) - both in New York; Université Paris-Cité, INSERM Unité 1148, FACT and Assistance Publique-Hopitaux de Paris, Hôpital Bichat, Paris (P.G.S.); South Australian Health and Medical Research Institute/SAHMRI, Adelaide, SA (P.A.), and Victorian Heart Institute, Monash University, Melbourne, VIC (S.J.N.) - both in Australia; the Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany (C.B.); Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA (K.W.M.); and London School of Hygiene and Tropical Medicine, London (S.J.P.).
Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
View Article and Find Full Text PDFSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
N Engl J Med
April 2024
From the Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (M.N.K.); the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.), the Diabetes Research Centre, University of Leicester, and the NIHR Leicester Biomedical Research Centre, Leicester (M.J.D.), and the Division of Cardiovascular Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester (F.Z.A.) - all in the United Kingdom; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); the Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Novo Nordisk, Søborg (G.K.H., D.V.M., M.B.T., T.J.J., K.L., M.L.L.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) - both in Denmark; the Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); the Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto (S.V.), and the University of Alberta, Edmonton (J.A.E.) - both in Canada; the College of Health and Medicine, Australian National University, Canberra, ACT, Australia (W.A.); the Heart Failure Unit, Cardiology Department, Rabin Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (T.B.-G.); Max Super Speciality Hospital, Saket, New Delhi, India (V.C.); the Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Östra, Gothenburg, Sweden (M.F.); the Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan (H.I.); the Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland (M.L.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER (Centro de Investigación Biomédica en Red) Cardiovascular - both in Valencia, Spain (J.N.); Instituto de Cardiologia J.F. Cabral, Corrientes, Argentina (E.P.); ASST (Azienda Socio Sanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy (M. Senni); the Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore (K.S.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.M.); the Medical University of Graz, Graz, Austria (D.V.L.); Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany (D.W.); and the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (S.J.S.).
Article Synopsis
- Obesity and type 2 diabetes are common in patients with heart failure with preserved ejection fraction, leading to significant symptoms, and there's a lack of approved treatments targeting this condition.
- A study assigned 616 patients with heart failure, obesity, and type 2 diabetes to receive either once-weekly semaglutide or a placebo for one year, measuring improvements in symptoms and weight.
- Results showed that those on semaglutide had significantly better improvements in symptom scores (KCCQ-CSS) and lost more body weight compared to the placebo group, along with other beneficial outcomes in physical activity and inflammation markers.
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
N Engl J Med
September 2023
From the Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) - both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) - all in the United Kingdom; the Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest School of Medicine, Winston-Salem, NC (D.W.K.); the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); the Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto (S.V.), and University of Alberta, Edmonton (J.E.) - both in Canada; the College of Health and Medicine, the Australian National University, Canberra, ACT, Australia (W.A.); Max Super Specialty Hospital, New Delhi, India (V.C.); the Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden (M.F.); the Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan (H.I.); the Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland (M.L.); the Institute for Clinical and Experimental Medicine, Prague, Czech Republic (V.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER (Centro de Investigación Biomédica en Red) Cardiovascular, Valencia, Spain (J.N.); Instituto de Cardiologia J.F. Cabral, Corrientes, Argentina (E.P.); ASST (Azienda Sociosanitaria Territoriale) Papa Giovanni XXIII, Bergamo, Italy (M. Senni); John Hopkins Hospital, Baltimore (K.S.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (P.V.M.); Medical University of Graz, Graz, Austria (D.L.); and Cardiology and Angiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany (D.W.).
Article Synopsis
- Heart failure with preserved ejection fraction (HFpEF) is more common in individuals with obesity and currently lacks approved treatments targeting this specific condition.
- A study involving 529 obese patients with HFpEF tested the weekly administration of semaglutide against a placebo over a 52-week period, measuring changes in symptoms, body weight, and physical activity.
- Results showed that semaglutide significantly improved symptoms (KCCQ-CSS score increase of 16.6 vs. 8.7 for placebo), reduced body weight (-13.3% vs. -2.6%), and enhanced walking distance (21.5 m vs. 1.2 m), with additional benefits noted in inflammation levels. *
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
N Engl J Med
September 2023
From the Atrial Fibrillation Network, Münster (P.K., A.G., U.S.), the Department of Cardiology, University Heart and Vascular Center Hamburg (P.K., T.T., N.B.), and the Institute of Medical Biometry and Epidemiology (A.-K.O., S.S., A.Z.), University Medical Center Hamburg-Eppendorf, and the German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck (P.K., T.T., N.B.), Hamburg, the Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital Paderborn, Paderborn (A.G.), the Department of Neuroepidemiology, Institute for Medical Informatics, Biometry, and Epidemiology, University Duisburg-Essen, Essen (H.C.D.), and the Heart Center, Segeberger Kliniken, Bad Segeberg (M.B.) - all in Germany; the Institute of Cardiovascular Sciences (P.K.) and the Centre for Patient Reported Outcome Research, Institute of Applied Health Research, the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, and the NIHR Applied Research Collaboration West Midlands (M.C.), University of Birmingham, Birmingham, the Cardiovascular and Cell Sciences Research Institute, St. George's University of London, and Imperial College London, London (A.J.C.), the Cardiac Department, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford (K.R.), and Liverpool Centre for Cardiovascular Science at University of Liverpool, John Moores University, and Liverpool Heart and Chest Hospital, Liverpool (G.Y.H.L.) - all in the United Kingdom; Unità Operativa Complessa Cardiologia-Azienda Ospedale Università di Padova, Padua, Italy (E.B.); the Department of Medical Science, Uppsala University, Uppsala, and the Department of Cardiology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro - both in Sweden (C.B.L.); the Department of Cardiology, Odense University Hospital, Odense, and the Department of Cardiology, Esbjerg Hospital-University Hospital of Southern Denmark, Esbjerg (A.B.), and the Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg (G.Y.H.L.) - all in Denmark; the Cardiology Department, Fernando Fonseca Hospital, Amadora, Portugal (N.C.); the Biostatistics Lab, School of Medicine, University of Crete (G.C.), and the Department of Cardiology, Heraklion University Hospital (E.S.), Heraklion, and the Biomedical Research Foundation Academy of Athens and Hygeia Hospitals Group, Athens (P.V.) - all in Greece; Medicine University Carol Davila, Colentina University Hospital, Bucharest, Romania (G.-A.D.); the Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (J.R.G.), and the Departments of Cardiology and Physiology, Maastricht University, Maastricht (U.S.) - both in the Netherlands; the Department of Internal Medicine III, Cardiology and Angiology, Innsbruck Medical University, Innsbruck (W.D.), and the Department of Cardiology, Medical University of Graz, Graz (D.S.) - both in Austria; the National Institute of Cardiovascular Surgery, Academy of Medical Sciences of Ukraine, Kyiv (B.K.); the Department of Cardiology and Internal Disease, Medical University of Gdansk, Gdansk (A.L.), and the Department of Electrocardiology and Heart Failure, Leszek Giec Upper Silesian Medical Center, Katowice (R.S.) - both in Poland; the Cardiology Division, European Georges Pompidou Hospital, Paris (E.M.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.); the Hospital Clinic, Universtitat de Barcelona, Barcelona, Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, and Centro de Investigacion Biomedica en Red Cardiovascular, Madrid - all in Spain (L.M.); the Department of Cardiology, University Hospital Antwerp, Edegem, Belgium (A.S.); the Cardiology Clinic, St. Anna University Hospital Sofia, Sofia Medical University, Sofia, Bulgaria (V.V.); and the Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W.).
Background: Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (as documented on a conventional electrocardiogram [ECG]) justifies the initiation of anticoagulants is not known.
View Article and Find Full Text PDFBuilding a Scaffold for Arteriovenous Fistula Maturation: Unravelling the Role of the Extracellular Matrix.
Int J Mol Sci
June 2023
Department of Internal Medicine, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands.
Vascular access is the lifeline for patients receiving haemodialysis as kidney replacement therapy. As a surgically created arteriovenous fistula (AVF) provides a high-flow conduit suitable for cannulation, it remains the vascular access of choice. In order to use an AVF successfully, the luminal diameter and the vessel wall of the venous outflow tract have to increase.
View Article and Find Full Text PDFTreatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications.
Eur Heart J
April 2023
Edith Wolfson Medical Center, Cardiology Department, Tel-Aviv University, Holon, Israel.
Article Synopsis
- The study examines the impact of treating paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) and its association with morbidity and mortality.
- A total of 201 patients were treated for moderate PVR using various interventions, including redo-TAVI, plug closure, and balloon valvuloplasty, with outcomes measured at 30 days and 1 year.
- Findings indicate that successful reduction of aortic regurgitation (AR) to mild levels significantly improved 1-year mortality rates, suggesting that treatment decisions and patient selection for PVR interventions need further research.
Bempedoic Acid and the Prevention of Cardiovascular Disease.
N Engl J Med
April 2023
From the Division of Cardiovascular Medicine and the Heart and Vascular Center, Brigham and Women's Hospital, and Harvard Medical School - both in Boston.
A Case Series of SARS-CoV-2 Reinfection in Elite Athletes.
Int J Environ Res Public Health
October 2022
The Heart and Vascular Center, Semmelweis University, H-1122 Budapest, Hungary.
Objectives: The actual frequency and the risk factors of SARS-CoV-2 reinfection is still a matter of intense scientific discussion. In this case series, we report three elite athletes who underwent COVID-19 reinfection with a short time frame.
Case Presentations: As a part of contact tracing, three speed skaters (22-, 24-, and 29-year-old males) were found to be SARS-CoV-2 positive by polymerase chain reaction (PCR) tests.
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.
N Engl J Med
December 2022
From the Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine (A.F., M.F.V., J.A. Kalish, J.J.S.), the Division of Vascular and Endovascular Surgery (M.T.M., M.B.S.) and the Department of Medicine (N.K.C.), Brigham and Women's Hospital, Harvard Medical School (M.R.J.), and the Section of Vascular Medicine and Intervention, Massachusetts General Hospital (K.R.), Boston, HealthCore, Watertown (T.H.H., S.F.A., M.J.C., M.O., M.M.), and the Division of Vascular Surgery, UMass Memorial Health, Worcester (A.S.) - all in Massachusetts; the Division of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco (M.S.C., W.G., P.A.S.), the Division of Vascular Surgery, UC San Diego Health, La Jolla (A.B.), Coastal Cardiology, French Hospital Medical Center, San Luis Obispo (L.C.C.), and the Division of Vascular Surgery and Endovascular Therapy, University of Southern California, Los Angeles (V.L.R.) - all in California; the Department of Interventional Radiology (J.A. Kaufman) and the Division of Vascular Surgery, School of Medicine (A.A.), Oregon Health and Science University, and the Operative Care Division, Portland VA Medical Center (M.C.K.) - all in Portland; the Heart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH (R.J.P., M.A.C., P.P.G.); the Department of Medical Imaging, University of Arizona Health Sciences, Tucson (M.D.D.), and the Division of Vascular Surgery, Peak Heart and Vascular, Glendale (N.G.) - both in Arizona; the National Heart, Lung, and Blood Institute, Bethesda, MD (D.R., G.S.); the Medical Device Innovation Consortium, National Evaluation System for Health Technology Coordinating Center, Arlington, VA (F.S.S.); the Department of Cardiovascular Diseases, Ochsner Clinical School, University of Queensland, Brisbane, Australia (C.J.W.); the Department of Interventional Radiology, Gundersen Health System, La Crosse, WI (E.A.); the Iowa Heart Center, Des Moines (D.K.C.); the Division of Vascular Surgery, Centre Hospitalier Universitaire de Quebec-Université Laval, Quebec City (Y.D.), and Dalhousie University, Division of Cardiac and Vascular Surgery, Department of Surgery, Nova Scotia Health Association, Halifax (C.R.H.) - both in Canada; the Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta (L.F.); the Division of Vascular and Endovascular Surgery, Maine Medical Center, Portland (K.A.G.); the Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City (B.M.H.); Westchester Medical Center and the Department of Surgery, Section of Vascular Surgery, New York Medical College - both in Valhalla, NY (I.A.L.); the Vascular Medicine Outcomes Program, Yale University, New Haven, CT (C.M.-H.); the Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis (R.M.); and the Department of Vascular Surgery, University of Helsinki, and Helsinki University Hospital - both in Helsinki (M.V.).
Background: Patients with chronic limb-threatening ischemia (CLTI) require revascularization to improve limb perfusion and thereby limit the risk of amputation. It is uncertain whether an initial strategy of endovascular therapy or surgical revascularization for CLTI is superior for improving limb outcomes.
Methods: In this international, randomized trial, we enrolled 1830 patients with CLTI and infrainguinal peripheral artery disease in two parallel-cohort trials.
Microfluidic bioprinting of tough hydrogel-based vascular conduits for functional blood vessels.
Sci Adv
October 2022
Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
Three-dimensional (3D) bioprinting of vascular tissues that are mechanically and functionally comparable to their native counterparts is an unmet challenge. Here, we developed a tough double-network hydrogel (bio)ink for microfluidic (bio)printing of mono- and dual-layered hollow conduits to recreate vein- and artery-like tissues, respectively. The tough hydrogel consisted of energy-dissipative ionically cross-linked alginate and elastic enzyme-cross-linked gelatin.
View Article and Find Full Text PDFAssociation between dietary patterns and depression: an umbrella review of meta-analyses of observational studies and intervention trials.
Nutr Rev
February 2023
is with the Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
Context: Depression is the most common causes of disease burden worldwide (GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet.
View Article and Find Full Text PDFMultiomics assessment of dietary protein titration reveals altered hepatic glucose utilization.
Cell Rep
August 2022
Department of Health Sciences and Technology, ETH Zürich, 8603 Schwerzenbach, Switzerland.
Dietary protein restriction (PR) has rapid effects on metabolism including improved glucose and lipid homeostasis, via multiple mechanisms. Here, we investigate responses of fecal microbiome, hepatic transcriptome, and hepatic metabolome to six diets with protein from 18% to 0% of energy in mice. PR alters fecal microbial composition, but metabolic effects are not transferable via fecal transplantation.
View Article and Find Full Text PDFProsthesis-patient mismatch following transcatheter aortic valve replacement for degenerated transcatheter aortic valves: the TRANSIT-PPM international project.
Front Cardiovasc Med
July 2022
IRCCS Policlinico S. Donato, Milan, Italy.
Article Synopsis
- Severe prosthesis-patient mismatch (PPM) is linked to negative outcomes after transcatheter aortic valve replacement (TAVR), and this study investigates its effects in patients undergoing a second TAVR (TAV-in-TAVR).
- The study analyzed data from 155 patients across 28 centers, finding that 6.5% experienced severe PPM and 14.2% moderate PPM, with higher rates in specific TAVR types.
- Results showed that severe PPM correlated with increased one-year all-cause mortality and worsened symptoms, although many patients saw improvement after receiving a new valve to treat the mismatch.
Outcomes of Redo Transcatheter Aortic Valve Replacement According to the Initial and Subsequent Valve Type.
JACC Cardiovasc Interv
August 2022
Centre for Cardiovascular Innovation, Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.
Background: As transcatheter aortic valve (TAV) replacement is increasingly used in patients with longer life expectancy, a sizable proportion will require redo TAV replacement (TAVR). The unique configuration of balloon-expandable TAV (bTAV) vs a self-expanding TAV (sTAV) potentially affects TAV-in-TAV outcome.
Objectives: The purpose of this study was to better inform prosthesis selection, TAV-in-TAV outcomes were assessed according to the type of initial and subsequent TAV.
The Impact of the Medical Device Directive to Medical Device Regulation Transition on Early Clinical Testing of Cardiovascular Devices.
J Soc Cardiovasc Angiogr Interv
July 2022
The Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, and The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Initial Experience Using Digital Variance Angiography in Context of Prostatic Artery Embolization in Comparison with Digital Subtraction Angiography.
Acad Radiol
April 2023
The Institute for Interventional and Diagnostic Radiology, University Hospital Frankfurt, Germany.
Rationale And Objectives: In previous clinical studies digital variance angiography (DVA) provided higher contrast-to-noise ratio (CNR) and better image quality in lower extremity angiography than digital subtraction angiography (DSA). Our aim was to investigate whether DVA has similar quality reserve in prostatic artery embolization (PAE). The secondary aim was to explore the potential advantages of the color-coded DVA (ccDVA) technology in PAE.
View Article and Find Full Text PDFReimagining Evidence Generation for Heart Failure and the Role of Integrated Health Care Systems.
Circ Cardiovasc Qual Outcomes
April 2022
Section of Cardiovascular Medicine and the Heart and Vascular Center, Yale University School of Medicine/Yale New Haven Health System, CT.
CT or Invasive Coronary Angiography in Stable Chest Pain.
N Engl J Med
April 2022
The authors' affiliations are as follows: the Heart and Vascular Center (P.M.-H., B.M., B.S., Z.D.D., M. Boussoussou) and the Department of Radiology, Medical Imaging Center (P.M.-H.), Semmelweis University, Budapest, Hungary; the Departments of Radiology (M. Bosserdt, E.Z., A.E.N., R. Haase, S.F., M. Rief, V.W., M.E., M.D.) and Cardiology and Angiology (M.L., H.D.), the Institute of Public Health (N.R., J.M.-N.), and the Institute of Biometry and Clinical Epidemiology (K.N.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin and DZHK (German Center for Cardiovascular Research) Partner Site Berlin (H.D., M.D.), Berlin Institute of Health and Berlin University Alliance (M.D.), Berlin, the Departments of Radiology (M.G.) and Cardiology (M.W.), University of Leipzig Heart Center, Leipzig, the Department of Cardiology, Alb Fils Kliniken, Göppingen (S.S., T.D.), the Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Munich (J.M.-N.), and the Department of Clinical Epidemiology and Applied Biostatistics, Universitätsklinikum Tübingen, Tübingen (L.M.S.-H., P.M.) - all in Germany; the Departments of Cardiology (K.F.K., A.D.K., T.E.) and Radiology (K.F.K., A.D.K.), Rigshospitalet, and the Department of Clinical Medicine, Faculty of Health and Medical Sciences (K.F.K., A.D.K., T.E., L.L., B.J.), and the Department of Public Health, Section for Health Services Research (K.S.H.), University of Copenhagen, Copenhagen, the Department of Cardiology, Herlev-Gentofte Hospital, Hellerup (L.L.), and the Department of Cardiology, Nordsjaellands Hospital, Hillerod (B.J.) - all in Denmark; the Department of Internal Medicine, Clinic of Cardiology (T.B., R. Hodas), and the Department of Radiology and Medical Imaging (M. Ratiu), George Emil Palade University of Medicine, Pharmacy, Science, and Technology, County Clinical Emergency Hospital Targu Mures (T.B.), and the Center of Advanced Research in Multimodality Cardiac Imaging, CardioMed Medical Center (I.B., I.R.) - all in Targu Mures, Romania; the Department of Cardiology, Southeastern Health and Social Care Trust, Belfast (P.D., C.O., S.K., S.R.), the Departments of Cardiology (G.D.) and Radiology (E.T.), Aintree University Hospital, the Department of Cardiology, Royal Liverpool University Hospital and the Institute for Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital (B.R., M. Fisher), and the Faculty of Health and Life Sciences, University of Liverpool (M. Fisher), Liverpool, Edge Hill University, Ormskirk (G.D.), the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow (C.B., C.D.), and Golden Jubilee National Hospital, Clydebank (C.B.) - all in the United Kingdom; the Departments of Cardiology (J.R.-P., F.X.V., B.G.B.) and Radiology (H.C.C.), Hospital Universitario Vall d'Hebron, Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Centro de Investigación Biomédica en Red, Madrid (J.R.-P., F.X.V., B.G.B.), the Departments of Cardiology (I.D., A.R.) and Radiology (I.L.), Basurto Hospital, Bilbao, Basque Foundation for Health Innovation and Research, Barakaldo, and the Basque Office for Health Technology Assessment, Vitoria-Gasteiz (I.G.-I.) - all in Spain; the Departments of Cardiology (A.E.) and Radiology (L. Zvaigzne), Paul Stradins Clinical University Hospital, and the University of Latvia (A.E.) - both in Riga, Latvia; the Departments of Cardiology (C.Š.) and Imaging Methods (V.S.), Motol University Hospital, Prague, Czech Republic; the Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, and the Department of Cardiology, Hospital of Lithuanian University of Health Sciences (G.Š., L. Zajančkauskiene) - both in Kaunas, Lithuania; the Faculty of Medicine, University of Novi Sad, and the Department of Cardiology, Institute for Cardiovascular Diseases of Vojvodina, Novi Sad (N.Č.A., F.A.), and the Department of Cardiology, Internal Medicine Clinic, Clinical Hospital Center Zemun, and the Faculty of Medicine, University of Belgrade, Belgrade (R.V., A.N.N.) - all in Serbia; the Departments of Radiology (J.D.D.) and Cardiology (M.H.), St. Vincent's University Hospital and School of Medicine, University College Dublin (J.D.D.), Dublin; the National Institute of Cardiology, Warsaw (C. Kępka, M.K.), and the Departments of Cardiology (M.I.-S.) and Radiology (D.K.), Provincial Specialist Hospital in Wroclaw, Wroclaw - both in Poland; the Department of Clinical Internal, Anesthesiologic, and Cardiovascular Sciences, Sapienza University of Rome, Rome (M.M.), the Department of Biomedical Sciences, Humanitas University, and IRCCS Humanitas Research Hospital (M. Francone), Milan, and the Department of Radiology, University of Cagliari (L.S.), and the Department of Radiology, Azienda Ospedaliera Brotzu (G.M.), Cagliari - all in Italy; the Department of Internal Medicine III, the Department of Cardiology (F.P.), and the Department of Radiology (G.F.), Innsbruck Medical University, Innsbruck, Austria; the Turku PET Center (J.K.) and Heart Center (M.P.), Turku University Hospital and University of Turku, and the Administrative Center, Health Care District of Southwestern Finland (M.P.) - all in Turku, Finland; the Department of Cardiology, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal (R.F., V.G.R.); and the European Clinical Research Infrastructure Network-European Research Infrastructure Consortium, Paris (C. Kubiak).
Background: In the diagnosis of obstructive coronary artery disease (CAD), computed tomography (CT) is an accurate, noninvasive alternative to invasive coronary angiography (ICA). However, the comparative effectiveness of CT and ICA in the management of CAD to reduce the frequency of major adverse cardiovascular events is uncertain.
Methods: We conducted a pragmatic, randomized trial comparing CT with ICA as initial diagnostic imaging strategies for guiding the treatment of patients with stable chest pain who had an intermediate pretest probability of obstructive CAD and were referred for ICA at one of 26 European centers.
It's a marathon not a sprint: the need for long-term monitoring of myocardial dysfunction in COVID-19.
Int J Cardiovasc Imaging
May 2022
The Heart and Vascular Center, The Christ Hospital Health Network, 2139 Auburn Ave, Cincinnati, OH, 45219, USA.